ROP

Roper Technologies (ROP) saw $63.7 million in net ETF selling on Friday, Oct. 30.

Roche announced today the U.S. Food and Drug Administration (FDA) 510(k) clearance of the cobas® eplex respiratory pathogen panel 3 (RP3). Designed for the automated cobas® eplex system, this flexible syndromic test offers up to five customizable panel configurations, enabling labs and clinicians to rapidly and accurately identify the cause of respiratory infections to help ensure timely and effec

Roche Holding (SWX:ROP) agreed a multi-program Antibody-Drug Conjugate collaboration with Hansoh Pharmaceutical, targeting oncology assets beyond China. The partners plan to co-develop and potentially commercialise a portfolio of ADC candidates, combining Roche platforms with Hansoh discovery capabilities. Roche reported positive late-stage trial data for several pipeline drugs, including new IgA

Emerson may extend its 70-year dividend growth streak as earnings rebound.

S&P 500 gap movers on October 30, 2026 included FDXF, VLTO, GILD and INCY on the upside, while INTC, RDDT and TWLO were among the gap-down decliners.

A substantial insider activity was disclosed on October 28, as Stipancich, EVP at Roper Technologies (NASDAQ:ROP), reported the exercise of a large block of company stock options. What Happened: The latest Form 4 filing

Roche Holding (SWX:ROP) has rolled out its VENTANA BAP1 (SP527) immunohistochemistry test worldwide, giving pathologists a highly specific tool to help distinguish malignant mesothelioma from other cancers using limited tissue samples. Roche Holding’s steady stream of product news in diagnostics and immunology has arrived alongside strong market interest, with the share price delivering a 12.2% 30

Dividend Aristocrats underperformed SPY in Sept. but rebounded sharply in Oct., narrowing the YTD gap. Check out the Nov. list of best dividend aristocrats here.